# Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Source: https://onco.cc/trials/nct05254171/  
OnCo record `nct05254171` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial testing Ivospemin in pancreatic ductal adenocarcinoma, now recruiting.

## Summary

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer is a phase 2/3 interventional study registered as NCT05254171, led by Panbela Therapeutics, and recruiting on the registry. Official title: A Randomised, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma. Planned enrolment is 600 participants (estimated). The study started in 2022-08-08 and primary completion is expected in 2026-08-29. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: ASPIRE
- Tags: ctgov-ingest
- Registry id: NCT05254171
- Phase: 2/3
- Setting: A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma
- Sponsor: Panbela Therapeutics
- Enrolled: 600

## Sources

- ClinicalTrials.gov NCT05254171: https://clinicaltrials.gov/study/NCT05254171

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Ivospemin](https://onco.cc/drugs/ivospemin/)
- companies: [Panbela Therapeutics](https://onco.cc/companies/panbela-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05254171.json